Sanofi to Aquire Inhibrx for $1.7 Billion
The acquisition adds a potential rare disease asset to Sanofi’s alpha-1 antitrypsin deficiency pipeline.
TOP NEWS on grunge world map | Image Credit: © Sean K - stock.adobe.com
On Jan, 23, 2024, Sanofi announced its planned acquisition of Inhibrx, a clinical-stage biopharmaceutical, in a deal valued at approximately $1.7 billion with a potential additional cash consideration of around $296 million. The acquisition will take place after the spin-off of non-INBRX-101 assets, such as its immune-oncology pipeline, into New Inhibrx. New Inhibrx will also retain its employees.
INBRX-101 is a human recombinant protein that can potentially normalize serum alpha-1-antitrypsin (AAT) levels in AAT deficiency (AATD) patients with less frequent doses. AATD is a genetic rare disease defined by low levels of AAT protein, which primarily affects the lung with progressive deterioration of the tissue. INBRX-101 works by inhibiting neutrophil elastase, an enzyme that causes lung tissue damage in AATD patients. INBRX-101 has the potential to reduce inflammation and prevent further deterioration of lung function in affected patients, according to a company press release.
INBRX-101 has finished a Phase I trial, where it demonstrated positive results in terms of safety and pharmacokinetics. It is being enrolled in a Phase II clinical trial to continue evaluating its potential as a treatment for AATD.
“The addition of INBRX-101 as a high-potential asset to our rare disease portfolio reinforces our strategy to commit to differentiated and potential best-in-class products,” said Houman Ashrafian, head of Research and Development at Sanofi, in the press release. “With our expertise in rare diseases and growing presence in immune-mediated respiratory conditions, INBRX-101 will complement our approach to deploy R&D efforts in key areas of focus and address the needs of the underserved AATD patients and communities.”
Source: Sanofi
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
